The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
It's a good RNS as far as ODX are concerned. They are expanding massively. ABC19 is under consideration in 30 countries. Antibody tests to help people assess their immunity levels after vaccination and to help medical authorities worldwide to assess booster requirements. Re-submission to the US FDA. That'll do me fine thanks.
I don't know what's wrong with the trolls. Are they mentally ill? And even posters like Hani? Telling us all he bought in recently for 50p. 80% up in the few months he's been invested and he's joining in with the trolls. Regulator hit the nail on the head yesterday on the matter of expectations. Greedy and/or impatient. Embarrassing reading your posts. What a horrible representation of investors.
Interesting that there have been a lot of comments re the margin on the abc test, so when it was £1.50 there was an 80p profit so cost 70p. Now it seems it is sold for £5.15 it no longer costs 70p but the cost of manufacture is closer to £3? As the commentators in the know reckon margin is 40%. One minor detail is that cost does not increase with price it is pretty much determined by raw materials and labour.
Even I've got bored of this guy....filtered
GAD and surescreen are what you should be looking at not Ablington they got binned off we aren't making their tests it's a mologic one you muppets
comical
Abington have not signed a Goverment contract your all getting mixed up Ablington is not ODx until you get.odx RNS I'd hold off making any rash decisions
For the year ending dec 31st, they reported 1M order. No other orders, not surprising as they were tied to UK gov during that period.
Its the forward statement (i.e. not historic) and other references to RTC that are clear in what is said and not said. Remember at this stage they are over 2 months into the next period.
No statement of actual orders. NONE No statement of how many they have produced.
what they said was
"Company anticipates significant sizeable orders"
(FUTURE TENSE, it is anticipation, there ARE NO CURRENT SIZEABLE ORDERS).
"The Company's Tier 1 order pipeline for ABC-19(TM) continues to grow"
"Pipeline opportunities"
Pipeline is one of those words that crops up time and time again in company reports in relation to orders. It's an airy fairy word that they know really doesn't mean a whole lot. THERE ARE NO ORDERS. Further passages continue to be all about interest, and opportunities, i.e. they are talking POTENTIALLY, not ACTUALLY.
So all this baseless speculation that the consortium had an overwhelming pentup "pre-order" book that would be unleashed on unshackling day (which is nearly a month ago) is seen for what it is.
Oh and find in that document of forward looking statements or in all the statements of what has happened since the end of the interim mention of MHRA approval for home use.....it is not there, still working on that.
they do say it is being distributed in the uk and "the Company is building stock to satisfy this anticipated demand". No numbers on that stock build, that would give some indication of what is going on. Without numbers those are meaningless statements. They talk about "delivery of orders before year end", which is end of June.
RTC test continues to be all potential, and ZERO actual. Kill any discussion of secret RTC orders. Whatever ODX is putting in the warehouse, they are spending their own money doing so, and its based on ANOTHER company getting orders.
Thinking Thinkin should go in the bin. Bye Thinkin
Well said
....and I have a sneaky feeling that capacity will be higher than 2m tests a week. 2.5m plus imo.
Looking forward to tge next 4 to 6 weeks....
Okehurst if that second paragraph reads correct it's massive. I wouldnt be surprised though wouldnt you have to RNS commencement of TT as its market sensitive?
With a focus on the word MINIMUM.
Yes. Minimum 25% of all orders.
Is the framework still in place that we will still get 25% of all orders??
Technical transfer.
Does it say hasn’t started or moving it through.
And 25% for Odx from memory another quality string our bow
Another interesting paragraph
Also in January 2021, Abingdon Health agreed a contract for technical transfer of a UK customer's COVID-19 antigen test into manufacturing and that project commenced in February 2021. The Company welcomed the news from Avacta plc in February 2021 regarding the very encouraging performance data on their COVID-19 antigen test. As a manufacturing partner for Avacta, the Company looks forward to moving their product through technical transfer in due course’
It appears Abingdon have not even started the TT with Avacta ?
Well done avacta supporters ,it’s seems they know how to communicate ,and still more silence from ODX , this silence is now contemptuous!
I liked this part -
"The Company is making good progress in the approval of AbC-19™ for testing in the US as well as with over 30 other countries worldwide. The Company has identified customers in seven countries that are being prioritised internally as Tier 1 commercial targets where, following registration of AbC-19™, the Company anticipates significant sizeable orders, ahead of the end of Abingdon Health's financial year. "
Interesting paragraph, relevant to ODX.
‘Good commercial progress with AbC-19™ COVID-19 rapid antibody test being evaluated in over 30 countries worldwide, with several contracts in late-stage negotiations subject to registration’